Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/14/2025
Locations: Adena Regional Medical Center, Chillicothe, Ohio
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105
Recruiting
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Intracranial Meningioma, Grade 2 Meningioma
Register for Updates
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
NCT04908735
Recruiting
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT. Improved transplant techniques and major improvements in survival mean that HSCT is being more widely used, and more mismatched grafts are being used. Bronchiolitis obliterans (BO) is a major limitation of pediatric HSCT success as BO is commonly diagnosed late in children, when lung injury is irreversible, leading to long term morbidity or even death. C... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
07/13/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)
Register for Updates
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2025
Locations: Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
NCT04098445
Recruiting
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently need... Read More
Gender:
ALL
Ages:
24 years and below
Trial Updated:
07/13/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Register for Updates
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810
Recruiting
QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator... Read More
Gender:
ALL
Ages:
22 years and below
Trial Updated:
07/12/2025
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Register for Updates
A Study of HBS-201 (Pitolisant Delayed-release)
NCT07051252
Recruiting
The purpose of this study is to assess the tolerability of HBS-201 when starting at a therapeutic dose in adult participants with narcolepsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Harmony Site 6, Canton, Ohio
Conditions: Narcolepsy
Register for Updates
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416
Recruiting
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/11/2025
Locations: 6065, North Canton, Ohio
Conditions: Bipolar Disorder I or II with a Major Depressive Episode
Register for Updates
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
NCT06597656
Recruiting
This is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory male participants with DMD and pre-existing antibodies to AAVrh74 over a period of 59 weeks.
Gender:
MALE
Ages:
Between 4 years and 8 years
Trial Updated:
07/11/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
07/11/2025
Locations: Neuro-Behavioral Clinical Research Inc., North Canton, Ohio
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates